基因组编辑
清脆的
嵌合抗原受体
电穿孔
多路复用
转染
计算生物学
微流控
细胞
T细胞
细胞生物学
HEK 293细胞
基因传递
生物
原电池
Cas9
基因组工程
翻译(生物学)
合成生物学
纳米技术
转录激活物样效应核酸酶
细胞疗法
重定目标
抗原
细胞内
脂质体
内体
T细胞受体
分子生物学
作者
You-Jeong Kim,Sungwon Bang,Aram J. Chung
出处
期刊:Small
[Wiley]
日期:2026-02-05
卷期号:22 (19): e12553-e12553
被引量:1
标识
DOI:10.1002/smll.202512553
摘要
T cell engineering is a transformative strategy for adoptive cell therapy, holding the key to treating a wide array of human diseases. However, clinical translation is limited by current intracellular delivery methods that compromise viability, induce stress responses, and restrict scalability. This study presents a microfluidic droplet mechanoporation system tailored for primary human T cells, enabling efficient, stable, and clinically scalable gene delivery. Delivery of 2000 kDa fluorescein isothiocyanate (FITC)-dextran achieves ∼98% efficiency and >90% post-treatment viability, even at high cell densities, supporting the rapid production of therapeutically relevant cell numbers. The platform efficiently delivers mRNA, achieving transfection efficiencies approaching 99%; further, chimeric antigen receptor (CAR)-encoding mRNA is successfully delivered to generate CAR-expressing T cells with tunable surface expression. Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 ribonucleoproteins are effectively delivered for both single and multiplex knockouts (TRAC and PDCD-1), achieving up to a 2.35-fold higher efficiency than electroporation. Longitudinal analyses confirm preserved viability, proliferation, genome integrity, and T cell phenotypic stability. Collectively, these results establish microfluidic droplet mechanoporation as a safe, efficient, and scalable platform for the clinical manufacturing of engineered T cell therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI